MARKET

PROF

PROF

Profound Med Corp
NASDAQ
12.75
-0.25
-1.92%
After Hours: 12.47 -0.28 -2.20% 16:02 01/27 EST
OPEN
12.90
PREV CLOSE
13.00
HIGH
13.19
LOW
12.40
VOLUME
45.83K
TURNOVER
0
52 WEEK HIGH
13.19
52 WEEK LOW
3.100
MARKET CAP
266.21M
P/E (TTM)
-9.0470
1D
5D
1M
3M
1Y
5Y
Profound Medical to Present at the 2022 Jefferies London Healthcare Conference
TORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased t...
GlobeNewswire · 11/08/2022 21:30
Profound Medical GAAP EPS of $0.24 beats by $0.61, revenue of $2.03M misses by $0.66M
Seekingalpha · 11/07/2022 22:06
Raymond James Upgrades Profound Medical to Strong Buy
Benzinga · 11/04/2022 18:55
BioAtla, TransMedics top healthcare gainers; Pulmonx, NeuroBo lead losers' pack
Seekingalpha · 11/04/2022 14:02
Profound Medical Announces Third Quarter 2022 Financial Results
TORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased t...
GlobeNewswire · 11/03/2022 20:05
Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow
TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased t...
GlobeNewswire · 10/13/2022 20:30
Profound Medical Highlights Four Year Follow-Up Data From TACT Pivotal Clinical Trial
TORONTO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets
Benzinga · 09/26/2022 12:01
Profound Medical to Participate in September Investor Conferences
TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased ...
GlobeNewswire · 09/06/2022 20:30
More
About PROF
Profound Medical Corp. is a Canada-based commercial-stage medical device company. The Company is focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare systems existing imaging infrastructure. The Company is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The Company is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Webull offers kinds of Profound Medical Corp stock information, including NASDAQ:PROF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PROF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PROF stock methods without spending real money on the virtual paper trading platform.